



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/624,395	07/24/2000	Keiko Neriishi	Q58690	6421

7590 05/09/2002

Sughrue Mion Zinn Macpeak & Seas PLLC  
2100 Pennsylvania Avenue NW  
Washington, DC 20037-3202

EXAMINER

FORMAN, BETTY J

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 05/09/2002

7

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/624,395

Applicant(s)

NERIISHI, KEIKO

Examiner

Betty J Forman

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 14 February 2002.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 7-20 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 7-20 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

Art Unit: 1634

### **FINAL ACTION**

1. This action is in response to papers filed 14 February 2002 in Paper No. 6 in which claims 1-6 were canceled and new claims 7-20 were added. All of the amendments have been thoroughly reviewed and entered. The previous rejections in the Office Action of Paper No. 4 dated 14 August 2001 are withdrawn in view of the amendments. All of the arguments have been thoroughly reviewed but are deemed moot in view of the amendments, withdrawn rejections and new grounds for rejection.

The examiner's Art Unit has changed from 1655 to 1634. Please address future correspondence to Art Unit 1634.

Currently claims 7-20 are under prosecution.

### ***Claim Rejections - 35 USC § 102***

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 7, 8, 10 and 13-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Shiraishi et al. (U.S. Patent No. 4,617,468, issued 14 October 1986). The claims are drawn to a microarray comprising a stimuable phosphor sheet and multiple kinds of biomolecules arrayed and fixed on the phosphor sheet. The claims are given the broadest reasonable interpretation consistent with the indefinite claim language wherein, as stated above, it is unclear how the biomolecules are arrayed and fixed and the specification wherein the microarray "has broad meanings embracing.... a macro array" (page 1, lines 14-16).

Art Unit: 1634

Regarding Claim 7, Shiraishi et al. disclose a microarray comprising a stimutable phosphor layer on a substrate wherein said phosphor layer has affixed thereto an array of biomolecules (Column 5, lines 53-65 and Column 13, lines 26-35).

Regarding Claim 8, Shiraishi et al. disclose a microarray comprising a stimutable phosphor layer on a substrate and a protective layer on the phosphor layer wherein the protective layer has affixed thereto an array of biomolecules (Column 12, line 67-Column 13, line 10).

Regarding Claim 10, Shiraishi et al. disclose the microarray wherein the biomolecule is an oligonucleotide (Column 13, lines 26-30).

Regarding Claim 13, Shiraishi et al. disclose a microarray comprising a stimutable phosphor layer on a substrate wherein said phosphor layer has affixed thereto an array of detecting bodies (Column 5, lines 53-65 and Column 13, lines 26-35).

Regarding Claim 14, Shiraishi et al. disclose a microarray comprising a stimutable phosphor layer on a substrate and a protective layer on the phosphor layer wherein the protective layer has affixed thereto an array of detecting bodies (Column 12, line 67-Column 13, line 10).

Regarding Claim 15, Shiraishi et al. disclose the microarrays of Claims 7, 8, 13 and 14 wherein the substrate is polyester (Column 7, lines 36-41).

### ***Claim Rejections - 35 USC § 103***

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1634

5. Claims 11, 12 and 16-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shiraishi et al. (U.S. Patent No. 4,617,468, issued 14 October 1986) in view of Davis et al. (Basic Methods in Molecular Biology, "DNA Hybridization", 1986, pages 84-87).

Regarding Claims 11, 12, 16 and 17, Shiraishi et al. teach a method for analyzing a biomolecule (Claims 11 & 12) and a sample (Claims 16 & 17) comprising: preparing a microarray comprising a stimutable phosphor layer and/or the protective layer wherein the stimutable phosphor layer has arrayed and affixed thereto an array of biomolecules/detecting bodies (i.e. labeled molecules e.g. proteins and nucleic acids); causing the stimutable phosphor sheet to store energy from the energy generating substance with which the fixed biomolecule is labeled; exposing the stimutable phosphor sheet to stimulating rays which cause the phosphor sheet to emit light in proportion to the amount of energy stored thereon and photoelectrically detecting the emitted light to detect the labeled biomolecule (Column 13, line 41-Column 14, line 5 and Column 14, line 49-Column 15, line 32). Shiraishi et al. teach the biomolecule is labeled and they teach providing the label by known methods (Column 13, lines 26-40) but they do not specifically teach labeling the fixed biomolecule by hybridization with a labeled biomolecule. However, labeling a biomolecule by hybridization with a labeled biomolecule was well known in the art at the time the claimed invention was made as taught by Davis et al. Specifically, Davis et al. teach hybridizing a labeled biomolecule with a biomolecule fixed on a support (page 85). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to modify the labeling of Shiraishi et al. wherein all of the arrayed and fixed biomolecules are radioactively labeled with the labeling taught by Davis et al. wherein only biomolecular probes are labeled and wherein the labeled probes hybridize to specific arrayed biomolecules to thereby detect only specific biomolecule(s) and based on the known hazards of radioactive labels, label biomolecular-specific probes and hybridizing the probes to the arrayed biomolecules thereby reducing the number of radio-labeled biomolecules and

Art Unit: 1634

reducing non-specific detection for the expected benefit of reduced biohazard risk and increased biomolecule-specific detection.

Regarding Claim 18, Shiraishi et al. the methods of Claims 11, 12, 16 and 17 wherein the substrate is polyester (Column 7, lines 36-41).

Regarding Claim 19, Shiraishi et al. teach the methods of Claims 11 and 12 wherein the biomolecule is an oligonucleotide (Column 13, lines 26-30).

6. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Shiraishi et al. (U.S. Patent No. 4,617,468, issued 14 October 1986) in view of Heller et al (U.S. Patent No. 5,632,957, issued 27 May 1997).

Regarding Claim 9, Shiraishi et al. teach a microarray comprising a stimuable phosphor layer on a substrate and a protective layer on the phosphor layer wherein the protective layer has affixed thereto an array of biomolecules (Column 12, line 67-Column 13, line 10) wherein the protective layer comprises polyacrylamide (Column 12, lines 13-20) and the biomolecules are affixed by electrophoretic resolution using "well known" methods (Column 13, lines 36-40) but they do not specifically teach the protective layer comprises poly-L-lysine. However, electrophoretic resolution on polyacrylamide comprising poly-L-lysine was well known in the art at the time the claimed invention was made as taught by Heller et al (Column 17, lines 54-65). Specifically, Heller et al teach a similar microarray comprising biomolecules arrayed and affixed to a polyacrylamide protective layer (Column 5, lines 3-8) wherein the surface of the polyacrylamide is functionalized with poly-L-lysine to thereby provide for covalent attachment of biomolecules to the surface (Column 18, lines 5-10). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the surface modification taught by Heller et al to the polyacrylamide surface of Shiraishi et al to thereby provide for covalent attachment of the biomolecules. One skilled in the art would

Art Unit: 1634

have been motivated to covalently attach the biomolecules of Shiraishi et al to thereby provide stable, specific and localized biomolecule binding for the expected benefit facilitating detection and analysis of the biomolecule and its interactions.

7. Claim 20 is rejected under 35 U.S.C. 103(a) as being unpatentable over Shiraishi et al. (U.S. Patent No. 4,617,468, issued 14 October 1986) in view of Davis et al. (Basic Methods in Molecular Biology, "DNA Hybridization", 1986, pages 84-87) as applied to Claim 12 above and further in view of Heller et al (U.S. Patent No. 5,632,957, issued 27 May 1997).

Regarding Claim 20, Shiraishi et al. teach a method for analyzing a biomolecule (Claims 11 & 12) and a sample (Claims 16 & 17) comprising: preparing a microarray comprising a stimutable phosphor layer and/or the protective layer wherein the stimutable phosphor layer has arrayed and affixed thereto an array of biomolecules/detecting bodies (i.e. labeled molecules e.g. proteins and nucleic acids); causing the stimutable phosphor sheet to store energy from the energy generating substance with which the fixed biomolecule is labeled; exposing the stimutable phosphor sheet to stimulating rays which cause the phosphor sheet to emit light in proportion to the amount of energy stored thereon and photoelectrically detecting the emitted light to detect the labeled biomolecule (Column 13, line 41-Column 14, line 5 and Column 14, line 49-Column 15, line 32) wherein the protective layer comprises polyacrylamide (Column 12, lines 13-20) and the biomolecules are affixed by electrophoretic resolution using "well known" methods (Column 13, lines 36-40) but they do not specifically teach the protective layer comprises poly-L-lysine. However, electrophoretic resolution on polyacrylamide comprising poly-L-lysine was well known in the art at the time the claimed invention was made as taught by Heller et al (Column 17, lines 54-65). Specifically, Heller et al teach a similar method wherein biomolecules arrayed and affixed to a polyacrylamide protective layer (Column 5, lines 3-8) wherein the surface of the polyacrylamide is functionalized with poly-L-lysine to

Art Unit: 1634

thereby provide for covalent attachment of biomolecules to the surface (Column 18, lines 5-10). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the surface modification taught by Heller et al to the polyacrylamide surface of Shiraishi et al to thereby provide for covalent attachment of the biomolecules. One skilled in the art would have been motivated to covalently attach the biomolecules of Shiraishi et al to thereby provide stable, specific and localized biomolecule binding for the expected benefit facilitating detection and analysis of the biomolecule and its interactions. Shiraishi et al. teach the biomolecule is labeled and they teach providing the label by known methods (Column 13, lines 26-40) but they do not specifically teach labeling the fixed biomolecule by hybridization with a labeled biomolecule. However, labeling a biomolecule by hybridization with a labeled biomolecule was well known in the art at the time the claimed invention was made as taught by Davis et al. Specifically, Davis et al. teach hybridizing a labeled biomolecule with a biomolecule fixed on a support (page 85).

### **Response to Arguments**

8. Regarding Claim 1, Applicant argues that Shiraishi et al teach biomolecules resolved in the support medium before of after the support medium is adhered to the phosphor sheet but they do not teach biomolecules (detecting bodies) affixed to or within the phosphor layer or protective layer as claimed. The argument has been considered but is not found persuasive because the claims are given the broadest reasonable interpretation consistent with the claim language and specification. The courts have stated that claims must be given their broadest reasonable interpretation consistent with the specification *In re Morris*, 127 F.3d 1048, 1054-55, 44 USPQ2d 1023, 1027-28 (Fed. Cir. 1997); *In re Prater*, 415 F.2d 1393, 1404-05, 162 USPQ 541, 550-551 (CCPA 1969); and *In re Zletz*, 893 F.2d 319, 321-22, 13 USPQ2d 1320, 1322 (Fed. Cir. 1989) (see MPEP 2111).

The claims are drawn to a micro array comprising a stimuable phosphor layer (and protective layer) on a substrate wherein the stimuable phosphor layer (or protective layer) have affixed thereto an array of biomolecules (detecting bodies). The specification teaches that steps of fixing and arraying are performed using a "known technique" (page 14, lines 3-5). The



Art Unit: 1634

specification provides an example of a technique (i.e. poly-L-lysine coating) but claims 7-8 and 10-19 are not limited to affixing via poly-L-lysine.

Shiraishi et al disclose biomolecules resolved on a support medium (protective layer) wherein the support medium is adhered to the phosphor layer (Column 5, lines 59-65). Given the broadest reasonable interpretation of the claims in view of the specification, the resolved biomolecules of Shiraishi et al are encompassed by the claims because the resolved biomolecules are in a fixed localized position on the support medium and because the support medium is fixed (adhered) to the phosphor layer. Because the biomolecules are fixed to support medium and because the support medium is fixed to the phosphor layer, the biomolecules are fixed to the phosphor layer via the support medium. Therefore, given the broadest reasonable interpretation of the claims, Shiraishi et al discloses the claimed microarrays.

Regarding Claim 4 and 6, Applicant argues that because Shiraishi et al do not teach affixing biomolecules or detecting bodies to the phosphor sheet or protecting layer and because Davis et al does not cure the deficiencies of Shiraishi et al the references do not teach all the elements of the rejected claims. The argument has been considered but is not found persuasive for the reasons stated above i.e. given the broadest reasonable interpretation of the claims, Shiraishi et al teach affixing biomolecules and detecting bodies to the phosphor sheet and protecting layer.

9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Art Unit: 1634

however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.


### **Conclusion**

10. No claim is allowed.


11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (703) 306-5878. The examiner can normally be reached on 6:30 TO 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-8724 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



BJ Forman, Ph.D.  
Patent Examiner  
Art Unit: 1634  
May 2, 2002



W. Gary Jones  
Supervisory Patent Examiner  
Technology Center 1600